Immune checkpoint inhibitors targeting PD-1 have revolutionized cancer treatment, offering durable responses in a subset of patients. However, as clinical use expands, so do the challenges, with primary and acquired resistance remaining major barriers to broader efficacy. While anti-PD1 monotherapy was initially approved for patients with high PD-L1 expression, the current landscape has shifted toward combination strategies that aim to enhance immune activation and circumvent resistance mechanisms.  

Emerging therapies such as anti-CTLA-4 inhibitors, and antibody-drug conjugates (ADCs) are at the forefront of this evolution. These next-generation therapeutic approaches require preclinical models that better replicate immuno-oncology dynamics, enabling more predictive evaluation of efficacy and safety. Join us as we explore how researchers can navigate the complexities of the post-PD1 landscape through optimized strategies and validated in vivo platforms.

Key topics included in this webinar: 

• Review the current challenges and resistance mechanisms in anti-PD-1 therapy 

• Discuss combinatorial approaches and next-generation immunotherapies 

• Explore preclinical models that support for efficacy and translational research 

Date:

Thursday, September 25, 2025

8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 5:00 PM CEST